Copyright
©The Author(s) 2015.
World J Gastrointest Pharmacol Ther. Nov 6, 2015; 6(4): 183-198
Published online Nov 6, 2015. doi: 10.4292/wjgpt.v6.i4.183
Published online Nov 6, 2015. doi: 10.4292/wjgpt.v6.i4.183
Table 1 Decline in rates of Helicobacter pylori eradication following first-line standard triple therapy
Country | Ref. | Publication | Treatment duration | Patients | Therapy regimen | Eradication rate (ITT) | Eradication rate (PP) |
South Korea | Na et al[177] | 2007 | 7 d | 3267 | Standard PPI | NA | 84.3% |
Cla 500 mg bid | |||||||
Amo 1 g bid | |||||||
Chung et al[178] | 2012 | 10 d | 80 | Lan 30 mg bid | 58.7% | 67.6% | |
Cla 500 mg bid | |||||||
Amo 1 g bid | |||||||
Japan | Asaka et al[179] | 2001 | 7 d | 96 | Lan 30 mg bid | NA | 90.7% |
Cla 200 mg bid | |||||||
Amo 750 mg bid | |||||||
Fujioka et al[180] | 2012 | 7 d | 3162 | Rab 10 mg bid | 80.7% | NA | |
Amo 750 mg bid | |||||||
Cla 200 mg bid | |||||||
Nishizawa et al[27] | 2012 | 7 d | 55 | Lan 30 mg bid | 74.5% | 80.4% | |
Cla 400 mg bid | |||||||
Amo 750 mg bid | |||||||
Nishida et al[181] | 2014 | 7 d | 134/134 | Eso 20 mg bid | 69.4%/73.9% | 76.9%/79.8% | |
Cla 400 mg bid | |||||||
Amo 750 mg bid | |||||||
Lan 30 mg bid | |||||||
Cla 400 mg bid | |||||||
Amo 750 mg bid | |||||||
Taiwan | Sheu et al[182] | 2000 | 7 d or 2 wk | 286 | Ome 20 mg bid | NA | 87.8% |
Amo 1 g bid | |||||||
Cla or Met bid | |||||||
Chen et al[117] | 2014 | 7 d | 73 | Rab 20 mg bid | 57.5% | 61.8% | |
Cla 500 mg bid | |||||||
Amo 1 g bid | |||||||
Turkey | Ozçay et al[183] | 2004 | 4 wk: PPI 2 wk:Cla, Amo | 102 | Ome or Lan | NA | 75.7% |
Cla 7.5 mg/kg bid | |||||||
Amo 20 mg/kg bid | |||||||
Kutluk et al[184] | 2014 | 10 d | 74 | Lan 1 mg/kg per day | 52.7% | 55.7% | |
Cla 20 mg/kg per day | |||||||
Amo 50 mg/kg per day | |||||||
Italy | Catalano et al[185] | 1999 | 10 d | 84 | Ome 20 mg bid | NA | 94.0% |
Cla 500 mg bid | |||||||
Amo 1 g bid | |||||||
Paoluzi et al[186] | 2010 | 7 d | 90 | Eso 20 mg bid | 66.0% | 75.0% | |
Cla 500 mg bid | |||||||
Amo 1 g bid | |||||||
Latin America | Greenberg et al[106] | 2011 | 14 d | 488 | Lan 30 mg bid | 82.2% | 87.1% |
Cla 500 mg bid | |||||||
Amo 1 g bid |
Table 2 Helicobacter pylori eradication rates following first-line sequential therapy
Country | Ref. | Publication | Treatment duration | Patients | Therapy regimen | Eradication rate (ITT) | Eradication rate (PP) |
South Korea | Lee et al[92] | 2014 | 10 d | 111 | 1st 5 d: Eso + Amo | 72.1% | 78.4% |
2nd 5 d: Eso + Cla + Met | |||||||
Lee et al[91] | 2015 | 10 d | 100 | 1st 5 d: Rab + Amo | 79.0% | 84.9% | |
2nd 5 d: Rab + Cla + Met | |||||||
China | Zhou et al[93] | 2014 | 10 d | 140 | 1st 5 d: Eso + Amo | 72.1% | 76.5% |
2nd 5 d: Eso + Cla + Tin | |||||||
Qatar | Ben Chaabane et al[94] | 2015 | 14 d | 106 | 1st 7 d: Rab + Amo | 66.0% | 76.0% |
2nd 7 d: Rab + Cla + Met | |||||||
Italy | Pontone et al[187] | 2010 | 10 d | 84 | 1st 5 d: Lan + Amo | 83.3% | 90.9% |
2nd 5 d: Lan + Cla + Met | |||||||
Spain | Molina-Infante et al[114] | 2010 | 10 d | 115 | 1st 5 d: Ome + Amo | 76.5% | 80.8% |
2nd 5 d: Ome + Cla + Met |
Table 3 Helicobacter pylori eradication rates following first-line concomitant therapy
Country | Ref. | Publication | Treatment duration | Patients | Therapy regimen | Eradication rate (ITT) | Eradication rate (PP) |
South Korea | Lim et al[104] | 2013 | 14 d | 78 | Rab 20 mg bid | 80.8% | 81.3% |
Amo 1 g bid | |||||||
Cla 500 mg bid | |||||||
Met 500 mg bid | |||||||
Lee et al[100] | 2015 | 7 d | 170 | Rab 20 mg bid | 79.4% | 94.4% | |
Amo 1 g bid | |||||||
Cla 500 mg bid | |||||||
Met 500 mg tid | |||||||
Thailand | Kongchayanun et al[188] | 2012 | 5 d/10 d | 55/55 | Rab 20 mg bid | 89.1%/96.4% | NA |
Amo 1 g bid | |||||||
Met 400 mg tid | |||||||
Cla 1 g qd | |||||||
Singapore | Ang et al[102] | 2015 | 10 d | 153 | PPI standard does | 81.7% | 95.4% |
Amo 1 g bid | |||||||
Cla 500 mg bid | |||||||
Met 400 mg bid | |||||||
Spain | Molina-Infante et al[97] | 2012 | 10 d | 209 | PPI standard does | 87.0% | 89.0% |
Amo 1 g bid | |||||||
Cla 500 mg bid | |||||||
Met 500 mg bid | |||||||
McNicholl et al[103] | 2014 | 10 d | 168 | Ome 20 mg bid | 87.0% | 91.0% | |
Amo 1 g bid | |||||||
Cla 500 mg bid | |||||||
Met 500 mg bid | |||||||
Latin America | Greenberg et al[106] | 2011 | 5 d | 489 | Lan 30 mg bid | 73.6% | NA |
Amo 1 g bid | |||||||
Cla 500 mg bid | |||||||
Met 500 mg bid |
Table 4 Helicobacter pylori eradication rates following first-line levofloxacin-containing therapy
Country | Ref. | Publication | Treatment duration | Patients | Therapy regimen | Eradication rate (ITT) | Eradication rate (PP) |
South Korea | Choi et al[189] | 2011 | 7 d | 98 | Ome 20 mg bid | 65.3% | 73.6% |
Lev 200 mg bid | |||||||
Amo 1 g bid | |||||||
China | Liao et al[122] | 2013 | 14 d | 81 | Lan 30 mg bid | 82.7% | 85.9% |
Lev 500 mg qd | |||||||
Amo 1 g bid | |||||||
Taiwan | Liou et al[190] | 2010 | 7 d | 217 | Lan 30 mg bid | 74.2% | 80.1% |
Lev 750 mg qd | |||||||
Amo 1 g bid | |||||||
Chen et al[117] | 2014 | 7 d | 73 | Rab 20 mg bid | 78.1% | 80.9% | |
Lev 500 mg bid | |||||||
Amo 1 g bid | |||||||
Spain | Molina-Infante et al[114] | 2010 | 10 d | 115 | Ome 20 mg bid | 80.8% | 82.6% |
Lev 500 mg bid | |||||||
Amo 1 g bid |
-
Citation: Kim SY, Choi DJ, Chung JW. Antibiotic treatment for
Helicobacter pylori : Is the end coming? World J Gastrointest Pharmacol Ther 2015; 6(4): 183-198 - URL: https://www.wjgnet.com/2150-5349/full/v6/i4/183.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v6.i4.183